Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction by Kupryjánczyk, J et al.
Apoptosis is an important mechanism of tissue homeostasis.
Alterations in cell survival may contribute to tumour development,
influence tumour biology and its response to chemotherapy.
Apoptosis may be triggered by p53-dependent or p53-independent
mechanisms that share downstream biochemical pathways. P53-
dependent apoptosis is stimulus specific. In several cell types
wild-type p53 protein is necessary for induction of apoptosis after
DNA damage (Lowe et al, 1993; Yonish-Rouach et al, 1993;
Bellamy, 1996). Other cellular insults that provoke p53-dependent
apoptosis are: non-physiological oncogene activation (Qin et al,
1994; Wagner et al, 1994; Wu and Levine, 1994; de Stanchina et
al, 1998; Zindy et al, 1998), hypoxia, heat shock and cytokine
deprivation (Bellamy, 1996; Evan and Littlewood, 1998). Thus,
defects in p53-dependent apoptotic response may contribute to
malignant transformation, tumour progression and tumour resis-
tance to DNA damage-inducing therapy.
P53-mediated apoptosis involves transcriptional repression of
bcl-2, activation of bax and bcl-xL, as well as immediate
interaction with proteins – mediators of apoptosis (Miyashita et al,
1994a, 1994b; Miyashita and Reed, 1995; Amundson et al, 1998).
Bcl-2 and bcl-xL proteins are inhibitors of programmed cell death,
while bax belongs to promotors. It is suggested that both bcl-2 and
bax proteins may participate in mitochondrial pore formation, and
thus influence the execution step of apoptosis. Bcl-2 and bcl-xL
anti-apoptotic proteins may be blocked by complex formation with
bax (Reed, 1997).
Little is known on apoptosis regulation in vivo. p53 gene alter-
ations are very frequent in ovarian cancer – they have been found in
81% of serous type tumours in our own material, and are rather an
early step in the development of ovarian cancer (Kupryjanczyk 
et al, 1993, 1995a; reviewed in Kupryjanczyk, 1996). One may
expect that p53 gene mutations will negatively influence p53-
dependent spontaneous and induced apoptosis. It is assumed that
poor response to DNA-damage in tumours bearing a p53 gene
mutation may cause genomic instability and tumour progression, as
well as resistance to DNA damage-inducing therapy. However,
studies on p53 status and response to cisplatin-based chemotherapy
have not given so far equivocal results (Righetti et al, 1996; De
Feudis et al, 1997). To our knowledge, spontaneous apoptosis has
not been evaluated in relation to p53 gene mutation neither in
ovarian or other tumour samples. Also, nothing is known about
possible prognostic value of spontaneous apoptosis in ovarian
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spontaneous apoptosis and p53 gene mutation, p53 protein accu-
mulation, growth fraction, bcl-2 expression, clinico-pathological
parameters and overall survival in ovarian carcinomas.
MATERIALS AND METHODS
Patients population
Patients ranged in age from 17 to 79 years (mean 56.9). The study
was performed on 71 tumours prior to chemotherapy: 64 ovarian,
four tubal and three disseminated peritoneal carcinomas of
mullerian type (i.e. serous). Tumours were staged according to the
criteria of the International Federation of Gynaecologists and
Obstetricians (Peterson et al, 1988; Creasman, 1989; Hirai et al,
1989). Ten tumours were in stage I, six were in stage IIC and 55
were in stage III or IV. Follow-up was available for 61 ovarian
cancer patients and ranged from 3 to 96 months (mean 25); 24
patients died of the disease.
Histopathological data
Tumours were classified according to the criteria of the World
Health Organization (Russell, 1994). Fifty-one tumours were of
the serous type and 20 of other types (seven endometrioid, four
mucinous, four clear cell, one transitional cell, one carcinosar-
coma, three undifferentiated). Tumour sections used for the apop-
tosis and immunohistochemical evaluations were re-examined as
to the histological and nuclear grades according to the criteria
given by Russell (1994) and Barber et al (1975) respectively
(Table 1).
Molecular genetic analysis
Thirty-one tumours were previously characterized as to the p53
gene mutation (Kupryjanczyk et al, 1993, 1995). The other 40
tumours were analysed by single strand conformational polymor-
phism (SSCP) method and direct sequencing. Briefly, exons 4–11
of the p53 were amplified by polymerase chain reaction (PCR;
with application of Perkin-Elmer PCR kit) on a programmable
thermal cycler (Biometra) with denaturation at 94°C, annealing at
52–65°C (depending on the exon) and extension at 72°C, each for
30 s (primer sequences and other details available from the
author). PCR products, denatured with 0.1 M sodium hydroxide,
were loaded to polyacrylamide gels (1:39 N,N¢-methylenebisacry-
lamide to acrylamide) (12% without glycerol and 10% with 10% 
glycerol). Electrophoresis was performed at 100 V for 16–24 h at
room temperature (RT). Normal DNA, amplified in the same PCR
reaction, denatured and non-denatured was run on each gel as a
control. The bands were visualized by silver-staining method
compilated from several procedures.
Sequencing of the SSCP variants was performed with the use of
dideoxy chain termination method according to the procedure
described in the Sequencing kit with sequenase version 2.0 (UBS,
Amersham) (sequences of primers used available from the author).
Radioactive labelling reaction was performed at 0°C for 5 min
using a-32P-dATP. The reaction products were electrophoresed on
8% polyacrylamide gels (N,N¢-methylenebisacrylamide and acryl-
amide ratio 1:19, 1 ´ TTE, 7M urea) at 80 W for 80–110 min. The
gels were exposed to X-ray films for 1–7 days.
Apoptosis analysis
Apoptotic cells were identified in paraffin-embedded material
with the use of the TUNEL method with application of a 
commercially available kit (ApopTag Plus, Oncor, cat no. S7101).
Apoptotic cells were counted at a 4003 magnification with the use
of a 0.49 cm2 graticule containing 36 grid points. Only cells with a
defined apoptotic morphology and of the total size corresponding
to the size of tumour cell nuclei were taken into account. The
counting was performed in four different areas most rich in apop-
totic cells, at least to 200 counts per area (may correspond to
6400–8000 of tumour cells evaluated in each case). Areas adjacent
to necrosis were avoided. Apoptotic index (AI) was defined as a
proportion of the apoptotic cells to the number of tumour cell
nuclei intersecting grid points.
Immunohistochemical analysis
P53 protein accumulation, bcl-2 and Ki-67 expressions were
detected immunohistochemically on paraffin-embedded material
after heat-mediated antigen retrieval. We used PAb1801 mono-
clonal antibody (1:500, Genosys) for the p53 protein, anti-bcl-2
monoclonal antibody (1:80, Dako, Glostrup, Denmark) for bcl-2
protein, and MIB-1 antibody (1:50, Immunotech, Marseille,
France) for Ki-67 antigen. Deparaffinized sections were boiled 2 ´
5 min (for p53 and bcl-2) or 3 ´ 5 min (for Ki-67) in a citrate
buffer (pH 6.0) at 700 W. Biotinylated goat anti-mouse IgG
(1:1500, cat. no. 816), peroxidase conjugated streptavidin (1:500,
cat. no. 309) (both from Immunotech, Marseille, France), and
DAB were used as a detection system. Normal mouse IgG (1:25,
Dako, Glostrup, Denmark) was used as a negative control.
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Table 1 Tumour characteristics (n = 71)
Apoptotic index
Range 0.024–0.182
Mean (s.d.) 0.112 (0.034)
Proliferation index
Range 3–90%
Mean (s.d.) 54% (0.206)
Histological type
Serous 51 (72%)
Other 20 (28%)
Histological differentiation
Good 4 (5.5%)
Moderate 14 (19.5%)
Poor 54 (75%)
Nuclear atypia
Strong 43 (60%)
Moderate 24 (33%)
Minor 5 (7%)
p53 protein accumulation
Absent 25 (35%)
Present 46 (65%)
bcl-2 expression
Negative, focal or trace 42 (59%)
Diffuse: weak, moderate or strong 29 (41%)
p53 gene mutation
Not detected 20 (28%)
Exons 4–6 31 (44%)
Exons 7–8 20 (28%)P53 protein accumulation was described as present or absent;
percentage of p53-positive cells was estimated semiquantitatively.
Bcl-2 expression was evaluated semiquantitatively and the
following staining categories were created: (1) negative, trace, or
focal positive; diffusely positive, either (2) weak, (3) moderate or
(4) strong. MIB-1-positive cells were counted in three different
foci most rich in proliferating cells to 500 counts per focus. A
mean proliferation index (PI) was defined for each case.
Statistical analysis
Number of apoptotic cells to the number of tumour cell nuclei was
evaluated as a dependent variable in a weighed multiple logistic
regression model (Williams, 1982). Independent variables
included: histological tumour type (serous vs others), two binary
variables indicating histological tumour grade (1 vs other, 2 vs
other) and nuclear grade (2 vs other, 3 vs other), p53 protein accu-
mulation (absent vs present), two binary variables indicating p53
gene status (no mutation vs mutation, a mutation in exons 7–8 vs
another status) and bcl-2 expression (negative, trace or focal vs
diffuse of any intensity). This analysis has been performed twice,
without and with inclusion of the proliferation index as an 
independent variable.
Bcl-2 expression was studied as a dependent variable with the
use of the Kruskal–Wallis test (Siegel and Castellan, 1988). This
analysis included histological tumour type and p53 gene mutation
as independent variables. Associations of bcl-2 expression with
histological or nuclear grades and with a histological type were
studied by a correlation coefficient gamma and Fisher’s test
respectively (Goodman and Kruskal, 1979; Mehta and Patel,
1983). For overall survival analysis we used Cox’s model and log-
rank test stratified according to FIGO stage. The level of signifi-
cance was set at 5%.
RESULTS
p53 status
p53 gene alterations have been found in 28 of the 40 new 
tumours (70%); the mutational spectrum was similar to that already
published for ovarian cancer, except that exon 5 mutations
accounted for about 50% of the alterations detected. Table 2 shows
a novel complex mutation of the p53 gene and four rare alterations
that have not been reported for ovarian cancer (other mutations will
be published elsewhere).
Altogether, among 71 tumours p53 gene mutations were present
in 51 (72%); 31 had mutations in exons 4–6 (44%) and 20 in exons
7–8 (28%). Forty-two mutations were missense and nine were
nonsense; 33 tumours showed loss of heterozygosity at p53. In 20
tumours (28%) no mutation has been detected in the sequences
studied, i.e. exons 4–11. P53 protein accumulation was observed
in 46 tumours (64%), and the percentage of positive cells ranged
from 30–100% (mean 81%).
Bcl-2 expression
Twenty tumours did not express bcl-2 protein, 11 showed only
trace reactivity, and the staining was focal in another 11 tumours.
Apparent diffuse bcl-2 expression of any intensity was observed in
29 tumours (41%); it was weak in 17, moderate in eight and very
strong in four tumours. The latter group included a poorly differ-
entiated serous carcinoma, and three cases of poorly differentiated
endometrioid carcinoma. The association of strong bcl-2 expres-
sion with endometrioid tumour type was statistically significant 
(P = 0.002). Bcl-2 expression was not associated with other para-
meters studied, in particular with p53 gene mutation or p53 protein
accumulation.
Apoptotic index
The AI ranged 0.024–0.182 (mean 0.112). In univariate evaluation
mean values of the AI for good, moderate and poor histological
differentiation were 0.06, 0.12 and 0.11 respectively; mean 
AI value for tumours without p53 gene mutation was 0.10, while
for tumours with p53 gene mutation it was 0.11 (without differ-
ences in respect to missense or nonsense mutation, or heterozy-
gosity status); mean AI value for tumours without, and with
diffuse bcl-2 expression was 0.11 and 0.10 respectively. The multi-
variate logistic regression model for proportion of apoptotic cells
retained the following variables at a 5% level of significance: good
histological differentiation (P = 0.0006), the serous tumour type 
(P = 0.002), the proliferation index (P = 0.023) and diffuse bcl-2
expression (P = 0.025) (parameters estimates are shown in Table
3). In the group of tumours other than serous, clear cell and
endometrioid carcinomas had the highest mean AI (0.16 and 0.12
respectively). In mucinous carcinomas the AI was lower (0.09)
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Table 2 A novel p53 gene mutation (tumour 204) and mutations not previously reported for ovarian cancer
Tumour no. Organ Type FIGO Exon Amino acid Alteration Change
262 Ovary Ser III 5 126 TAC®TAA Tyr to Stop
98 Peritoneum Ser III 5 176?–178? CCCCC®CCCC
1 bp del Stop at 246
100 Ovary Ser III 6 199 31 bp del
(13355–85) Stop at 246
205 Ovary Ser II 7 230 10 bp del
(14015–24) Stop at 246
204 Ovary Endo III 8 296 22 bp del
(14555–76)
303 (A)GC®(A)GT Stop at 344
Ser, serous; Endo, endometrioid.than in the serous type (0.10). In contrast to low histological grade,
low nuclear grade was positively associated with the AI, but it was
of borderline significance (P = 0.071). The presence of the p53
gene mutation did positively influence the AI, but it was at the
border of significance (P = 0.082). This association was much
stronger (P = 0.011) in the initial analysis, without inclusion of the
proliferation index into the model. P53 protein accumulation did
not influence the AI.
Survival analysis
Overall survival analysis was performed on the group of 61
ovarian cancer patients. It included the AI (≤ 0.10 vs > 0.10), clin-
ical stage (FIGO I, II vs III, IV), histological grade (1, 2 vs 3), p53
protein accumulation (absent vs present), p53 gene mutation
(absent vs present) and the proliferation index (≤ 46.46 vs 
> 46.46). The AI and PI were cut off arbitrarily at the 33rd
percentile. The only factor that influenced overall survival was
FIGO stage (RR = 5.7; 95% confidence interval (CI) 1.27–25.59;
P = 0.023) and p53 protein accumulation, when the group was
stratified for FIGO (log-rank = 4.34, P = 0.037).
DISCUSSION
Wild-type p53 may simultaneously induce growth arrest and apop-
tosis within the same cell (Liebermann et al, 1995). Biochemical
pathways for these two processes are different: the first one
involves transcriptional activation of waf1, the other – interactions
with bcl-2 family genes. These pathways are independent, but may
communicate, and a switch of one signal to the other may occur
(Bellamy, 1996; Amundson et al, 1998). P53-mediated control of
cell proliferation and death involves other proteins also – to date at
least 20 p53 effector genes have been recognized, which partici-
pate in regulation of growth arrest, apoptosis or both (Amundson
et al, 1998). The present and other studies on human tumours show
a spectacular (opposite to the physiological one) effect of impaired
p53 function on tumour proliferation (Henriksen et al, 1994;
Kupryjanczyk et al, 1995b; Rohlke et al, 1997). The same cannot
be observed in relation to apoptosis. We and others have not found
an association between apoptosis and p53 protein accumulation
(Diebold et al, 1996; McMenamin et al, 1997; Yamasaki et al,
1997). Our study has shown that p53 gene mutation does not
contribute to attenuation of spontaneous apoptosis in ovarian
carcinomas. On the contrary, it has a positive influence on this
process mainly by increasing growth fraction. Thus, our results
suggest that spontaneous apoptosis in ovarian carcinomas does not
depend on wild-type p53 protein. This is intriguing, because spon-
taneous apoptosis in the tumours studied might have also been a
response to DNA damage, inappropriate oncogene activation and
different environmental changes, such as hypoxia, that specifically
induce p53.
Evidence is accumulating that cell proliferation and apoptosis
are linked. Examples of proteins with both growth-promoting and
pro-apoptotic function are c-myc, adenovirus E1A, and E2F-1
transcription factor (Evan and Littlewood, 1998). Other authors
did report a positive association between apoptosis and growth
fraction or mitotic index in ovarian carcinomas (McMenamin et al,
1997; Yamasaki et al, 1997).
Our study has shown that degree of histological differentiation
and histological tumour type are among major determinants of
spontaneous apoptosis in ovarian carcinomas. The apoptotic index
was negatively associated with good histological differentiation,
which was also observed by other authors (Diebold et al, 1996;
Yamasaki et al, 1997). We have shown that this association is not
dependent on low growth fraction in well differentiated tumours.
In contrast to good histological differentiation, good nuclear
differentiation showed a positive influence on spontaneous apop-
tosis, although it was at the border of significance. The AI may
depend on histological tumour type, too. It was higher in carci-
nomas other than serous. In fact, among that group of tumours the
clear cell and endometrioid carcinomas had the highest AI, while
mucinous carcinomas had the lowest, even lower than the serous
type. High AI in clear cell and endometrioid carcinomas may be
dependent on strong bax expression in most cases of these histo-
logical types, as shown by Tai et al (1998).
It has been shown for some cell lines that p53 may repress tran-
scription of bcl-2, and activate that of bax (Miyashita et al, 1994a,
1994b; Miyashita and Reed, 1995). We have not found an associa-
tion between p53 gene mutation or protein accumulation and bcl-2
expression. Bcl-2 expression was dependent on histological
tumour type: the strongest expression was seen in endometrioid
carcinomas (described also by Diebold et al, 1996), despite poor
tumour differentiation and the relatively high AI. Generally
tumours with diffuse bcl-2 expression had significantly lower AI,
which is in accord with its anti-apoptotic function. Thus, evidence
is accumulating that there are major differences among histo-
logical tumour types not only in respect to p53 function, but also
apoptosis and expression of apoptosis-related genes.
Apoptosis and growth fraction did not gain a prognostic signifi-
cance in our analysis. We have hypothesized that p53 protein accu-
mulation may not have a prognostic value because of different
biological significance of p53 gene mutations. In our analysis, the
presence of p53 gene mutation did not influence overall survival
time. The only parameters prognostically significant were clinical
stage and p53 protein accumulation. Prognostic value of p53
protein accumulation has been a matter of controversy. In this
aspect, our result supports studies by Klemi et al (1995), Herod et
al (1996) and Rohlke et al (1997). Therefore, it seems that p53
protein accumulation (with or without underlying gene alterations)
is a more adequate manifestation of impaired p53 protein function
than gene alterations that include also nonsense errors without
protein accumulation.
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Table 3 Parameters associated with the apoptotic index in ovarian
carcinomas
Parameters estimates t Two-sided 
(standard error) P-value
Histological tumour type
Serous vs other –0.306 (0.095) –3.226 0.002
Histological grade
1 vs other –0.777 (0.215) –3.612 0.0006
Nuclear grade
3 vs other 0.317 (0.173) 1.834 0.071
Proliferation index 0.462 (0.198) 2.33 0.023
Bcl-2 expression
Diffusely positive vs
negative, focal, trace –0.178 (0.077) –2.297 0.025
p53 gene mutation
Present vs absent 0.2164 (0.093) 1.766 0.082ACKNOWLEDGEMENTS
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